REDWOOD CITY, Calif.,
March 7, 2011 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that Richard
King, President and Chief Executive Officer, will present at
the Cowen and Company 31st Annual Health Care Conference at the
Boston Marriott Copley Place. The presentation is scheduled
for Wednesday, March 9, 2011 at
8:45 a.m. ET.
The presentation will be webcast live and can be accessed
through http://www.wsw.com/webcast/cowen3/acrx/. For those who are
not available to listen to the live broadcast, the presentation
will be archived and available through http://www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
Based in Redwood City, CA,
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain. AcelRx's lead product candidate, the
ARX-01 Sufentanil NanoTab(TM) PCA System, which has completed Phase
2 clinical development, is designed to solve the problems
associated with post-operative intravenous patient-controlled
analgesia (IV PCA) which has been shown to cause harm to patients
following surgery because of the side effects of morphine, the
invasive IV route of delivery and the inherent potential for
programming and delivery errors associated with the complexity of
infusion pumps. AcelRx has two additional product candidates which
have completed Phase 2 clinical development: ARX-02 for the
treatment of cancer breakthrough pain, and ARX-03 for providing
mild sedation, anxiety reduction and pain relief for patients
undergoing painful procedures in a physician's office.
SOURCE AcelRx Pharmaceuticals, Inc.